Full Text View
Tabular View
Study Results
Related Studies
Zaleplon 10 mg Capsules Under Non-Fasting Conditions
This study has been completed.
Study NCT00829868   Information provided by Teva Pharmaceuticals USA

First Received on January 26, 2009.   Last Updated on July 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Healthy
Interventions listed in this trial
Zaleplon 10 mg Capsules
SONATA® 10 mg capsules
Additional drug interventions recognized in this trial
Zaleplon
More general drug interventions related to this trial
Anticonvulsants
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Teva Pharmaceuticals USA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services